UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/590,207	10/26/2006	Toru Tsukagoshi	129146	4406	
25944 OLIFF & BERI	7590 11/30/200 RIDGE, PLC	EXAMINER			
P.O. BOX 3208	350	DENTZ, BERNARD I			
ALEXANDRIA, VA 22320-4850			ART UNIT	PAPER NUMBER	
			1625		
			MAIL DATE	DELIVERY MODE	
			11/30/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Арі	olication No.	Applicant(s)	Applicant(s)		
		10,	/590,207	TSUKAGOSHI E	TSUKAGOSHI ET AL.		
		Exa	nminer	Art Unit			
			nard Dentz	1625			
 Period for	The MAILING DATE of this communi	cation appears	on the cover sheet w	ith the correspondence a	ddress		
WHICH - Extens after S - If NO p - Failure Any re	RTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE MAIN IN THE	AILING DATE of 37 CFR 1.136(a). unication. tutory period will appwill, by statute, cause	OF THIS COMMUNI In no event, however, may a ly and will expire SIX (6) MOI the application to become Al	CATION. reply be timely filed NTHS from the mailing date of this BANDONED (35 U.S.C. § 133).			
Status							
2a)□ 1 3)□ 8	Responsive to communication(s) file. This action is FINAL . Since this application is in condition to the condition of the condition is accordance with the practic	tb)⊠ This action	on is non-final. except for formal mat	• •	ne merits is		
	n of Claims	о инаст да ра	ne Quayle, 1000 O.L	7. 11, 400 0.0. 210.			
4 5)⊠ (6 6)⊠ (7)⊠ (6 8)□ (6 Applicatio 9)□ T 10)□ T	he specification is objected to by the he drawing(s) filed on is/are: Applicant may not request that any objections.	e withdrawn from the wed. The rejected. The rejected is a second of the drawing in the drawing	ction requirement. d or b)⊡ objected to ng(s) be held in abeya	nce. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority ur	nder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice 3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (Pation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date <u>9-17-2009</u> .	TO-948)	Paper No(Summary (PTO-413) s)/Mail Date Informal Patent Application 			

Claims 1-3, 5, 6, 8-11, 32 and 33 are rejected under 35 U.S.C. 102(b) as being anticipated by Tanikawa et al, US Patent 6,066,631 cited by applicants. It discloses a genus of 4-(substituted amino) 2,2-dialkyl-chroman—ols which are substituted on benzo moiety of the chroman nucleus by a substituted amino or a substituted sulfonylamino containing moiety. Although only compounds where said latter amino substituents are substituted on the 6-position are specifically disclosed., the instant 7-substituted amino compounds are included. See col. 1-14 for the generic disclosure. See col. 9, lines 15-22 for the preferred position of the latter.

The compounds are disclosed as useful in the treatment of arrhythmia at col. 76, lines 35-38.

Claims 1-3, 5, 6, 8-11, 32 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tanikawa et al, supra. If the 102 rejection is not upheld a 103 rejection also applies because of the above mentioned disclosure. It is obvious to make the position isomer. The position in this case refers to the 7-position versus the 6-position of the preferred compounds of the reference.

See also the specific compounds named in the Tables. See e.g., col. 29, first Table, compound 11; col. 29, second table compounds 8 and 11; and col. 33, top table compound 10.

Claims 4 and 7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Application/Control Number: 10/590,207 Page 3

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/ Bernard Dentz/

Primary Examiner, Art Unit 1625